Investor Presentaiton slide image

Investor Presentaiton

Investor Presentation First six months of 2018 Slide 12 Oral semaglutide demonstrated a consistent reduction in HbA1c and body weight in the completed PIONEER trials In completed PIONEER trials, oral semaglutide lowered HbA1c by 1.1-1.5%-points by end of trial¹ Mean change in HbA1c (%-points) 0.0% -0.5% -1.0% PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7 TILIT In completed PIONEER trials, oral semaglutide lowered body weight by ~3-5 kg by end of trial¹ Mean change in weight (kg) 0.0 -1.0 -2.0 -3.0 PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7 -1.1%* -1.5% -1.3%* -1.2%* -4.0 -3.5* -1.5%* -1.4%* -4.1* -5.0 -4.7* -2.0% -6.0 -5.0* -2.9* 1 Hypothetical estimand, Mixed Model for Repeated Measurement (MMRM) * Statistically significant vs comparator (PIONEER 1 vs placebo; PIONEER 2 vs empagliflozin 25 mg; PIONEER 3 vs sitagliptin 100 mg; PIONEER 4 vs Victoza® 1.8 mg; PIONEER 7 vs sitagliptin 100 mg) Note: results shown are: PIONEER 1 for 26 weeks with 14 mg oral semaglutide, PIONEER 2 and 4 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7 for 52 weeks with a mixed dose novo nordisk
View entire presentation